Immuneering (IMRX) Income from Continuing Operations (2020 - 2026)
Immuneering (IMRX) recorded quarterly Income from Continuing Operations of 13974630.0 in Q1 2026, down 17.52% quarter-over-quarter from 11891675.0 in Q4 2025, and up 7.12% on a YoY basis from 13045595.13 in Q1 2025.
Immuneering (IMRX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Immuneering's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 13974630.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 7.12% year-over-year to 13974630.0; the TTM figure through Mar 2026 stood at 55265061.0 (up 10.87% YoY), while the FY2025 annual figure was 56336563.0, up 8.36% from the prior year.
- Income from Continuing Operations was 13974630.0 for Q1 2026 at Immuneering, down from 11891675.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 11503250.0 in Q2 2022 to a low of 18142915.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 13960329.12 across 5 years, with a median of 13974630.0 in 2026.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations tumbled 105.36% in 2022, then soared 34.46% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 13468839.0 in 2022, then declined by 15.44% to 15547844.0 in 2023, then retreated by 16.69% to 18142915.0 in 2024, then surged by 34.46% to 11891675.0 in 2025, then decreased by 17.52% to 13974630.0 in 2026.
- The last three Income from Continuing Operations figures came in at 13974630.0 (Q1 2026), 11891675.0 (Q4 2025), and 14964875.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Immuneering | 255.40 Mn | 255.40 Mn | - | -13.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.97 Mn |
| Dec 31, 2025 | -11.89 Mn |
| Sep 30, 2025 | -14.96 Mn |
| Jun 30, 2025 | -14.43 Mn |
| Mar 31, 2025 | -15.05 Mn |
| Dec 31, 2024 | -18.14 Mn |
| Sep 30, 2024 | -14.73 Mn |
| Jun 30, 2024 | -14.09 Mn |
| Mar 31, 2024 | -14.52 Mn |
| Dec 31, 2023 | -15.55 Mn |
| Sep 30, 2023 | -13.07 Mn |
| Jun 30, 2023 | -12.34 Mn |
| Mar 31, 2023 | -13.85 Mn |
| Dec 31, 2022 | -13.47 Mn |
| Sep 30, 2022 | -12.97 Mn |
| Jun 30, 2022 | -11.50 Mn |
| Mar 31, 2022 | -12.79 Mn |
| Dec 31, 2021 | -10.97 Mn |
| Sep 30, 2021 | -8.53 Mn |
| Jun 30, 2021 | -7.99 Mn |